AMR Roundtable Part 2: The Need For Patient Perspectives To Reinforce Urgency Of Antimicrobial Drug Development
Scrip spoke with the CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at BIO about the challenges of antimicrobial drug development. This second part of the roundtable centers on the lack of patient advocates in the area of antimicrobial-resistant infections.
You may also be interested in...
The World Health Organisation has released a list of 12 bacteria it says pose the greatest threat to human health as a way of urging governments and the drug development industry to incentivize and launch an R&D response against the increasing global issue of antibiotic resistance.
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.